Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts

S Ghavami1,2,3,4, RH Cunnington3, S Gupta3, B Yeganeh1,2,3, KL Filomeno3, DH Freed3, S Chen3, T Klionsch4, AJ Halayko1,2,5, E Ambrose3, R Singal6 and IMC Dixon*1,3

Transforming growth factor-β1 (TGF-β1) is an important regulator of fibrogenesis in heart disease. In many other cellular systems, TGF-β1 may also induce autophagy, but a link between its fibrogenic and autophagic effects is unknown. Thus we tested whether or not TGF-β1-induced autophagy has a regulatory function on fibrosis in human atrial myofibroblasts (hATMyofbs). Primary hATMyofbs were treated with TGF-β1 for fibrogenic and autophagic responses. Using immunoblotting, immunofluorescence and transmission electron microscopic analyses, we found that TGF-β1 promoted collagen type I and fibronectin synthesis in hATMyofbs and that this was paralleled by an increase in autophagic activation in these cells. Pharmacological inhibition of autophagy by bafilomycin-A1 and 3-methyladenine decreased the fibrotic response in hATMyofb cells. ATG7 knockdown in hATMyofbs and ATG5 knockout (mouse embryonic fibroblast) fibroblasts decreased the fibrotic effect of TGF-β1 in experimental versus control cells. Furthermore, using a coronary artery ligation model of myocardial infarction in rats, we observed increases in the levels of protein markers of fibrosis, autophagy and Smad2 phosphorylation in whole scar tissue lysates. Immunohistochemistry for LC3β indicated the localization of punctate LC3β with vimentin (a mesenchymal-derived cell marker), ED-A fibronectin and phosphorylated Smad2. These results support the hypothesis that TGF-β1-induced autophagy is required for the fibrogenic response in hATMyofbs.

Cell Death and Disease (2015) 6, e1696; doi:10.1038/cddis.2015.36; published online 19 March 2015

Interstitial fibrosis is common to many cardiovascular disease etiologies including myocardial infarction (MI), diabetic cardiomyopathy2 and hypertension.3 Fibrosis may arise due to maladaptive cardiac remodeling following injury and is a complex process resulting from activation of signaling pathways, such as TGF-β1.4 TGF-β1 signaling has broad-ranging effects that may affect cell growth, differentiation and the production of extracellular matrix (ECM) proteins.5,6 Elevated TGF-β1 is observed in post-MI rat heart7 and is associated with fibroblast-to-myofibroblast phenotype conversion and concomitant activation of canonical Smad signaling.8 The result is a proliferation of myofibroblasts, which then leads to inappropriate deposition of fibrillar collagens, impaired cardiac function and, ultimately, heart failure.9,10

Autophagy is necessary for cellular homeostasis and is involved in organelle and protein turnover.11–14 Autophagy aids in cell survival by providing primary materials, for example, amino acids and fatty acids for anabolic pathways during starvation conditions.15,16 Alternatively, autophagy may be associated with apoptosis through autodigestive cellular processes, cellular infection with pathogens or extracellular stimuli.17–20 The overall control of cardiac fibrosis is likely due to the complex functioning of an array of regulatory factors, but to date, there is little evidence linking autophagy with fibrogenesis in cardiac tissue.11–18,21,22

Recent studies have demonstrated that TGF-β1 may not only promote autophagy in mouse fibroblasts and human tubular epithelial kidney cells15,23,24 but can also inhibit this process in fibroblasts extracted from human patients with idiopathic pulmonary fibrosis.25 Moreover, it has recently been reported that autophagy can negatively15 and positively25–27 regulate the fibrotic process in different model cell systems. In this study, we have explored the putative link between autophagy and TGF-β1-induced fibrogenesis in human atrial myofibroblasts (hATMyofbs) and in a model of MI rat heart.
Results

TGF-β1 simultaneously induces fibrosis and autophagy in hATMyofbs. TGF-β1 is but one of an array of factors shown to be involved in the induction of cardiac fibrosis, as demonstrated in overexpression and knockout models. As atrial fibrillation is a serious clinical problem with high incidence in society and is linked to fibrosis of atrial tissues, we investigated whether or not there was an association between TGF-β1-induced fibrosis and autophagy in hATMyofbs. Primary hATMyofbs constitute a clinically relevant model for the study of TGF-β1-induced fibrosis and autophagy. Our results show that TGF-β1 (10 ng/ml) induces significant increases in the synthesis of collagen type I and fibronectin in the presence of LC3II lipidation and increases Smad2 and Smad3 phosphorylation and p62 degradation (Figures 1a and b). We also showed that TGF-β1 treatment significantly did not affect the viability of hATMyofbs cells (Figure 1c) while conversely it is associated with a significant induction of their proliferation at 72 and 120 h after treatments when compared with 48-h cultures (Figure 1d; P < 0.01). Fibrillar collagen type I and fibronectin deposition was also confirmed using transmission electron microscopic (TEM) images from hATMyofbs, which were stimulated with TGF-β1 at 10 ng/ml for 96 h (Figures 1e and f). Figures 1e and f indicate an increase of fiber deposition after TGF-β1.

![Image](129x244 to 470x553)

Figure 1  TGF/β1 simultaneously induces fibrosis and autophagy in hATMyofbs. (a) Primary hATMyofbs (passages 2–5) were treated with TGF-β1 (10 ng/ml) for 0–120 h, and cell lysates were collected. Immunoblots were probed for the autophagy hallmark protein LC3II, p62, as well as indicator proteins of the fibrogenic response in fibroblasts (i.e., collagen and fibronectin). TGF-β1 induced LC3II lipidation, with parallel increases in collagen and fibronectin protein expression and Smad2 and Smad3 phosphorylation. Data were normalized to GAPDH levels. Results are the means of three independent experiments from four different donors. (b) Densitometric analysis of LC3II, p62, collagen and fibronectin levels in hATMyofbs. Data are the means of three independent experiments from three different donors. For each experiment, LC3II, collagen and fibronectin levels were compared with those from time-matched controls and normalized to GAPDH levels. (c and d) TGF-β1 treatment does not affect cell viability of hATMyofbs, but it associated with their proliferation at 72 and 120 h. hATMyofbs were exposed to TGF-β1 (10 ng/ml) for the indicated time points (48, 72, 120 h), and cell viability and proliferation was measured as described in the Materials and Methods section in three different culture experiments (n = 3). TGF-β1 treatment was not associated with any significant changes in cell viability (*P < 0.01) while it induced significant hATMyo by proliferation at 72 and 120 h compared with 48 h (P < 0.01). (e and f) hATMyofbs were either untreated or treated with 10 ng/ml TGF-β1 for 96 h. Cells were then imaged by TEM at a magnification of 15,600 (a) and 6750 (f). Extracellular fiber deposition (collagen type I or fibronectin) was compared between the control and TGF-β1 treatment groups. TGF-β1 increased extracellular fiber deposition. hATMyofbs were either untreated or treated with 10 ng/ml TGF-β1 for the indicated time points (0–120 h). The cell culture medium was collected and concentrated with filter tube (MESH 20 kDa). Collagen and fibronectin were probed in concentrated cell culture media. TGF-β1 induced mature and immature collagen secretion at different time points. hATMyofbs were either untreated or treated with 10 ng/ml TGF-β1 for 96 h. Cells were then imaged by TEM at a magnification of 3600 (control, top panel left), 7500 (control, top panel right) and for TGF-β1 treatment (right panel 2750, left panel 27 500 and (l) 127 000). An autophagosome is highlighted in panel (j). hATMyofbs treated with TGF-β1 (10 ng/ml, 96 h) showed increased LysoTracker Red DND-99 staining (a marker of lysosomal activation) and an increase in punctuate staining for LC3II (green), a marker of autophagy, and LC3II/lysosomal co-localization. hATMyofbs were treated with TGF-β1 (10 ng/ml, 96 h) and were immunostained for LC3II (green) and lysosomes (red). Ten different fields (10 cells in each field) were randomly chosen in control and TGF-β1 treatment and were counted manually by an operator. The percentage of yellow cells, which indicated LC3II lipidation and increases Smad2 and Smad3 phosphorylation and p62 degradation (Figures 1a and b). We also showed that TGF-β1 treatment significantly did not affect the viability of hATMyofbs cells (Figure 1c) while conversely it is associated with a significant induction of their proliferation at 72 and 120 h after treatments when compared with 48-h cultures (Figure 1d; P < 0.01). Fibrillar collagen type I and fibronectin deposition was also confirmed using transmission electron microscopic (TEM) images from hATMyofbs, which were stimulated with TGF-β1 at 10 ng/ml for 96 h (Figures 1e and f). Figures 1e and f indicate an increase of fiber deposition after TGF-β1.
Autophagy modulates heart fibrosis

S Ghavami et al

Cell Death and Disease

Figure 1 Continued.
treatment. TGF-\(\beta_1\) stimulation increased collagen \(\beta_2\) secretion from hATMyofbs cells compared with time-matched control cells, which also proved TGF-\(\beta_1\)-induced fibrosis (western blotting analysis in Figure 1g). Possible TGF-\(\beta_1\) autophagy induction was further investigated using TEM images from hATMyofbs stimulated with TGF-\(\beta_1\) at 10 ng/ml for 96 h. Figures 1h and i clearly show autophagosome and autophagolysosomes in hATMyofbs stimulated with TGF-\(\beta_1\). Moreover, our immunocytochemistry data indicate punctate LC3\(\beta\) II staining and lysosomal activation in hATMyofbs treated with TGF-\(\beta_1\) (Figure 1j), with a significant \((P<0.001)\) increase in the number of cells. This is consistent with the autophagy activation in these cells. To obtain more quantitative assessment of the induction of autophagy, we used bafilomycin-A1 (Baf-A1; 10 nM) to block the fusion of autophagosomes and lysosomes and assess the presence of autophagy flux. As shown in Figure 2a, we demonstrate autophagic flux, for example, autophagosome delivery to lysosomes and autophagolysosome formation, by co-treating hATMyofbs with TGF-\(\beta_1\) and Baf-A1 for 48 and 96 h. TGF-\(\beta_1\)-induced accumulation of LC3-II was enhanced in the presence of Baf-A1, which supports the suggestion that TGF-\(\beta_1\) enhances autophagosome synthesis.

### Discussion

In this study, we have shown that TGF-\(\beta_1\) simultaneously induces autophagy and fibrosis in human atrial myofibroblasts and that pharmacological inhibition of autophagy is associated with a parallel reduction in TGF-\(\beta_1\)-induced fibrosis. Our findings highlight a linkage between autophagy and elevated matrix protein synthesis by hATMyofbs and TGF-\(\beta_1\) activation in scar tissue from a rat model of MI. These results strongly support the hypothesis that TGF-\(\beta_1\)-induced fibrosis depends upon its ability to induce autophagy.

Basal level autophagy occurs in all cell types but can be rapidly upregulated as an adaptive response to generate intracellular nutrients and energy under conditions of cellular stress. Autophagy is a tightly regulated process that is a highly conserved, phylogenetically ancient process. It is observed in yeast cells to mammalian tissues and has roles in various biological events, such as cellular remodeling during fibrosis.
Autophagy modulates heart fibrosis
S Ghavami et al

Figure 2

Continued
Autophagy modulates heart fibrosis
S Ghashani et al

**Figure 2.** TGF-β-induced autophagy is a requisite of TGF-β-induced pro-fibrosis in hATMMyofbs. (a) Primary hATMMyofbs were treated with TGF-β (10 ng/ml) in the presence of the autophagy inhibitor Baf-A1 (10 nM) or 3-MA (2.5 mM) for the indicated durations. Western blotting analysis revealed that inhibition of autophagy abrogated the fibrogenic effects of TGF-β (i.e., decreased collagen type 1 and fibronectin expression levels), whereas this treatment did not affect Smad2 or Smad3 phosphorylation. Equal protein loading was confirmed using GAPDH levels. Results are the means from three independent experiments using cells from three different donors. (b and c) Densitometric analysis of collagen type 1 and fibronectin levels in hATMMyofbs, which were stimulated with TGF-β or autophagy inhibitors (i.e., Baf-A1 (10 nM) or 3-MA (2.5 mM)) (c). Inhibition of autophagy significantly decreased collagen type 1 and fibronectin biosynthesis. Data are the means of three independent experiments using hATMMyofbs from three different donors. For each experiment, collagen type 1 and fibronectin levels were compared with those from time-matched controls and normalized to GAPDH levels. (d-f) Protein required for autophagy induction (Atg7) were stably knocked down in hATMMyofbs. Atg7 knocked down cells and their correspondence scramble infected cells were treated with TGF-β (10 ng/ml) for 48 and 96 h. Whole-cell lysates were extracted and then collagen type 1 and fibronectin expression levels were measured in the cell lysates. Protein loading was confirmed using GAPDH. (g) Densitometry analysis showed that Atg7 knockdown was associated with a significant (P<0.01) decrease of TGF-β-induced fibronectin biosynthesis in hATMMyofbs. (h) Protein required for autophagy induction increases TGF-β-induced fibrogenic effects. hATMMyofbs were pretreated with Rapamycin (4 h, 1000 nM) and then co-treated with TGF-β (10 ng/ml) for the indicated duration. LC3 lipidation, collagen type 1 expression, fibronectin expression, total Smad2/3 and Smad2 phosphorylation were measured in whole-cell lysates. Protein loading was confirmed using GAPDH. (i) Densitometry analysis showed that Rapamycin (1000 nM) significantly (P<0.01) increased TGF-β-induced fibronectin and collagen type 1 expression in hATMMyofbs. **P<0.01

---

development, differentiation, adaptation to changing environmental conditions, lifespan extension and response to environmental stress. In contrast, uncontrolled autophagy can drive cells towards type II programmed cell death, which is morphologically distinct from type I (e.g., apoptosis), and may be involved in the pathogenesis of a number of different diseases. This notwithstanding, a growing body of evidence points to autophagy as being important for cell survival and that an accumulation of autophagosomes may simply reflect a survival response to deadly stress aimed at ridding the cell of misfolded proteins or damaged organelles. Although cellular necrosis is generally accepted as the major mechanism for cell death in post-MI cardiac tissues, we note several recent reports that address the occurrence of autophagy in post-MI myocardium. Kanamori et al. have reported that autophagy is activated in cardiomyocytes and specifically that autophagic activity was particularly strong in salvaged cardiomyocytes bordering the infarcted area. Kanamori et al. have reported that during both subacute and chronic post-MI stages, for example, at 1 week and 3 weeks after MI, respectively, autophagy is activated in surviving cardiomyocytes, as they have demonstrated by the upregulated expression of microtubule-associated protein-1 light chain 3-II (LC3-II), p62 and cathepsin D and by electron microscopic findings. Their finding closely correlate with our findings in the rat experimental model of infarction that we have currently used (Figure 3b). Whelan et al. have also recently suggested a possible role for autophagy in post-MI tissues, and thus the argument that autophagy occurs in and may regulate cellular responses in post-MI heart in addition to necrosis is established in the literature. With regard to the question of whether autophagy could be a back-up mechanism for fibrosis – there are several hypotheses that we are testing in our current research program. One of these mechanisms addresses the role of autophagy in providing energy for pro-fibrotic protein biosynthesis.

The ECM provides a scaffold that surrounds and supports cells in virtually all tissues. Tissue fibrosis is the structural basis for a variety of chronic human diseases, including cardiovascular fibrosis, liver cirrhosis, end-stage kidney disease, systemic sclerosis and various autoimmune diseases, and causes irreversible damage to affected tissues, including inotropic and lusitropic dysfunction in the heart. Despite recent progress in understanding the mechanisms underlying the pathogenesis of tissue fibrosis, and
Figure 3 Concomitant occurrence of autophagy, fibrosis and Smad2 phosphorylation in scar tissue from post-MI rats. (a–c) Western blotting analysis of infarct scar and non-infarcted (NI) control tissues from post-MI experimental animals confirmed the concomitant occurrence of fibrosis (i.e., elevation of fibronectin levels), autophagy (i.e., elevation of LC3β-II and Atg5-12 levels) and Smad2 phosphorylation, with Smad phosphorylation (p-Smad) being a hallmark of TGF-β1 activation, in scar tissue 2 weeks after MI. This time point was chosen as it reflects the active healing phase after MI. (d) Densitometry analysis of fibronectin and LC3β-II of tissues from post-MI experimental animals showed that both proteins have increased in scar area compared with sham area at 2 and 4 weeks time point. (e–g) Immunofluorescence histochemical analysis of sham and scar tissue showed the co-localization of LC3β with vimentin (e), EDA-Fibronectin (f) and phospho Smad2 (g) in scar compared with sham area.
developing novel therapeutic strategies to reverse it, there are no effective therapeutic treatments presently available to combat fibro-proliferative diseases.

TGF-β induces both autophagy and fibrosis in many tissues, and the concomitant occurrence of autophagy and fibrosis in many diseases has been previously observed. We used pharmacological inhibitors of autophagy, including the class III phosphoinositol 3-kinase inhibitor, 3-MA, and the lysosomal ATPase pump inhibitor, Baf-A1, to show that inhibition of autophagy significantly attenuates TGF-β-mediated pro-fibrotic effects in hATMyofbs. Our results are supported by studies demonstrating that autophagy is necessary for induction of fibrosis in hepatic cells.

We extended our in vitro observations using hATMyofbs by including an in vivo model of MI in rats. Cardiac fibroblasts are

**Figure 3** Continued
key players in maintaining homeostasis of the heart's ECM. Cardiac ECM remodeling is well documented in post-MI hearts in the infarct zone, as well as in both ventricles remote to the infarct scar. In other cardiac diseases (such as hypertension), globalized fibrosis is likely a primary contributor to the progression of congestive heart failure. It is well known that TGF-β1 is expressed in the heart and that, following MI, the levels of TGF-β1 increase in the scar area. Here, we show that indicators of autophagic induction (i.e., LC3β II, Atg5-12 conjugation, fibronectin synthesis and Smad2 phosphorylation) are increased in lysates of cardiac scar tissue at 2 and 4 weeks post-MI, as compared with sham-operated heart tissues. These findings correlate with the temporal window for infarct scar healing in post-MI rat heart following coronary arterial occlusion. Conversely, samples taken at 24 and 48 h, and at 8 weeks post-MI, show no signs of autophagic activation in terms of LC3β II, Atg5-12 conjugation, fibronectin synthesis or Smad2 phosphorylation, in either scar or sham-operated control tissue. Together, these data establish the coincidence of autophagy and fibrosis in the presence of increased TGF-β1 levels in a rat model of MI and directly correlate with our in vitro, cell-based studies with hATMyofbs. More generally, as blockade of autophagy in fibrogenic cells from different organs also attenuates fibrogenesis, it appears that autophagy is an evolutionarily conserved, core pathway that contributes to, and regulates, the fibrotic response in a wide range of tissues.

Our findings underscore the parallel roles played by autophagy and fibrosis in the processes involved in cellular activation and enhanced ECM production in the heart. They also provide a novel framework for understanding the basis of cardiac fibrotic disease, as well as the regulation of fibrosis in general. Finally, these results highlight autophagy as a putative novel therapeutic target in attenuating fibrosis in fibro-proliferative diseases.

**Materials and Methods**

**Reagents.** Cell culture media and supplements (i.e., SMEM, DMEM, fetal bovine serum (FBS), penicillin/streptomycin (Pen/Strep) and insulin/transferrin/selenium (ITS)) were obtained from Gibco (Thermo Fisher Scientific Inc., Waltham, MA, USA), and collagenase type IV was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) (sc-8786). Phenylmethanesulfonyl fluoride (PMSF), protease inhibitor cocktail, β-glycerol 3-phosphate and simvastatin were obtained from Sigma-Aldrich (St. Louis, MO, USA), and enhanced chemiluminescence (ECL) reagents were purchased from Amersham-Pharmacia Biotech Inc. (The NCR, NJ, USA). Baf-A1 and 3-MA were from Sigma-Aldrich, and Lysotracker Red DND-99 was obtained from Molecular Probes (Eugene, OR, USA). All other reagents were of ACS Grade or better. Human ATG7 shRNA and human scrambled shRNAs were purchased from Santa Cruz Biotechnology.

**Antibodies.** Rabbit anti-human/mouse/rat LC3β II was from Sigma-Aldrich. Rabbit anti-human Atg5, Smad2/3, phospho-Smad2, phospho-Smad3, Atg7 and p62 antibodies were purchased from Cell Signaling (Danvers, MA, USA). Rabbit anti-human fibronectin, mouse anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and goat anti-human collagen 1α2 were obtained from Santa Cruz Biotechnology. Horseradish peroxidase- and fluorochrome-conjugated secondary antibodies were purchased from Sigma-Aldrich.

**Primary hATMyofb cell culture preparation.** Approval was obtained from the Research Ethics Board of the University of Manitoba for the collection of atrial tissue from patients undergoing cardiac surgical procedures. Written, informed consent was obtained from each patient prior to tissue collection. We declined samples from patients with atrial fibrillation, and our patient donors are typically preinfarct coronary artery bypass graft (CABG) candidates. Furthermore first- and second-passage human atrial fibroblasts (P1 and P2) from this patient group show a high degree of similarity among preparations from different individual patients, as simple plating of these cells in two dimensions on plastic plates has a greater impact on cellular phenotype than any other factor. These conditions tend to provide equalization of phenotype prior to experimentation and thus allow meaningful comparisons between cells harvested from different patients.

**Cell viability assay.** Human atrial myofibroblasts (passage 1 or 2) were cultured in 96-well plates (20 000 cells per well). After reaching a confluency of around 60%, they were treated with TGF-β1 (10 ng/ml) for different time points (48, 72, 120). At each time point, the cell viability was assessed using MITT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay as we have described before. Primary fibroblasts (and myofibroblasts) adhere more readily and quickly to culture plates than other cell types in the heart resulting in a very pure population of fibroblasts/myofibroblasts during isolation procedures. However, once in culture, fibroblasts/myofibroblasts readily differentiate (~16 h) into myofibroblasts. Thus in using these cells, we can be assured that the cells are myofibroblasts, and we have previously published the characteristics of these cells during different passages. In addition, the cells are isolated from the atrial appendage of deceased human hearts, which already have a substantial population of myofibroblasts.

**Cell proliferation assay.** Human atrial myofibroblasts (passage 1 or 2) were cultured in 96-well plates (20 000 cells per well). After reaching a confluency of around 60%, they were treated with TGF-β1 (10 ng/ml) for different time points (48, 72, 120). At each time point, the cell numbers was measured using cell counting in the presence of Trypan blue as we have described before. Immunochemistry. Tissue was prepared according to procedures as described with the exception of tissue fixation in 95% ethanol. Briefly, hearts were excised from animals killed at 2 weeks after left ventricular coronary ligation surgery. Isolated left ventricular tissue was frozen in embedding medium at –80°C to be used for sectioning. Frozen tissue blocks were cut in 7-μm thick transverse sections across the ventricular scar area using a Microm HM 550 cryotome and placed on slides. Tissue was then fixed in 4% parafomaldehyde for 15 min washed 3 x in 1% PBS buffer and permeabilized with 0.1% triton X-100 for 15 min. Tissue slices were washed 3 x 15 min in 1% PBS and incubated overnight with 4°C with primary antibodies (Vimentin 1:200, LC3 1:200, ED-A fibronectin 1:100 and pSmad2 1:20) in 1% bovine serum albumin. Tissue slices were washed the next day 3 x 15 min with 1% PBS and incubated for 90 min at room temperature with fluorescently conjugated secondary antibodies. Slides were washed again 3 x for
15 min with 1% PBS and then dried. Cover slips were then mounted onto slides using Prolong Gold antifade reagent (Thermo Fisher Scientific Inc.) with DAPI. Images were visualized and captured using an epifluorescence equipped microscope (Leica Microsystems TCS SP5 Confocal Microscope, Buffalo Grove, IL, USA) at x>40 magnification.

Stable gene silencing: lentiviral delivery of shRNA. Human atrial myofibroblasts (passage 1) were infected with ATG7 shRNA- and noncoding shRNA-lentiviral particles (Santa Cruz Biotechnology), and stable clones were selected using puromycin.13,34

Stimulation of hATMyofbs with TGF-β1. Primary human atrial myofibroblasts (passage 1 or 2), hATMyofb ATG7 KO, hATMyofbs infected with noncoding shRNA, MEF (WT), and ATG5 KO MEF were grown in 100-mm cell culture dishes up to 80% confluency in DMEM+10% FBS. In preparation for experimentation, cells were starved in DMEM+1% ITS for 48 h, and then stimulated with TGF-β1 (10 ng/ml) in DMEM+1% ITS for 0–120 h. In experiments using Bal-A1, 3-MA, and Rapamycin, the cells were first pretreated with Bal-A1 (10 nM), 3-MA (2.5 mM), and Rapamycin (1000 nM) for 4 h prior to the addition of TGF-β1 (10 ng/ml) for various time points thereafter.

Secreted collagen Iα2 assay. Collagen Iα2 secretion was assessed by immunoblot analysis. Primary human atrial myofibroblasts (passages 2–5) were seeded in 100-mm dishes. Cells were treated with TGF-β1 for the indicated time points (0–120 h), the supernatant was collected centrifuged at 10,000 g for 20 min, transferred to 50-ml filter tubes (20-ml mesh, Amicon, Millpore, Bedford, MA, USA), and centrifuged at 3000 × g for 35 min. The remaining supernatant on top of the filter was collected, and western blotting analysis was performed using a goat anti-Collagen Iα2 antibody (Santa Cruz Biotechnology, USA).

Immunoblotting. Western blotting analysis was used to detect LC3II/ I, Atg5-12, Smad2/3, phospho-Smad2, phospho-Smad3, collagen type 1α2, fibronectin, p62, Atg7, Atg5 and GAPDH as previously described.13 Briefly, cells were washed with Tris-buffered saline (TBS), and protein extracts were prepared in lysis buffer (20 mM Tris-HCl (pH 7.5), 0.5% Nonidet P-40, 0.5 mM PMSF, 100 μM β-glycerol 3-phosphate and 0.5% protease inhibitor cocktail). Following centrifugation at 13,000 × g for 10 min, supernatant protein content was assessed according to the bicinchoninic acid method. Proteins were size-fractionated by SDS-PAGE under reducing conditions and subsequently transferred to PVDF membranes. Blots were blocked with 10% non-fat dried milk in TBS+0.02% Tween 20 overnight with primary antibodies in 5% non-fat dried milk in TBS+0.02% Tween 20 and then incubated reducing conditions and subsequently transferred to PVDF membranes. Blots were blocked with 10% non-fat dried milk in TBS+0.02% Tween 20 and then incubated overnight with primary antibodies in 5% non-fat dried milk in TBS+0.02% Tween 20 at 4 °C. Blots were subsequently incubated with HRP-conjugated secondary antibodies for 1 h at RT in 3% non-fat dried milk in TBS+0.02% Tween 20, and proteins were visualized with ECL on X-ray film.

Immunocytochemistry, confocal imaging and TEM. In immunocytochemistry studies, hATMyofbs were grown overnight on Tcove slips and then treated with simvastatin (10 μM) or vehicle for 72 h. Lysozymes were stained with LysoTracker Red DND-99 (100 nM × 10 min) prior to fixation in 4% paraformaldehyde/120 mM sucrose and permeabilization with 3% Triton-X-100. Cells were then incubated with rabbit anti-LC3II/ I IgG (1:200) with a corresponding fluorochrome-conjugated secondary antibody. Fluorescence images were captured and analyzed using an Olympus Fluoview multi-laser confocal microscope (Olympus Canada Inc., Toronto, ON, Canada). For TEM, cells were fixed with 2.5% glutaraldehyde in PBS (pH 7.4) for 1 h at 4 °C and postfixed with 1% osmium tetroxide prior to embedding in Epon. TEM was performed using a Philips CM120 (Koninklijke Philips N.V. (Philips), Amsterdam, Netherlands) at 80 kV on ultra-thin sections (100 nm on 200 mesh grids) stained with uranyl acetate and counter-stained with lead citrate as previously described.13,34

Experimental rat model of MI. Experimental protocols for animal studies were approved by the Animal Care Committee of the University of Manitoba, Canada and conform to the guidelines established by the Canadian Institutes of Health Research and the Canadian Council on Animal Care (2001). MI was induced in male Sprague-Dawley rats (150–175 g) by surgical occlusion of the left coronary artery, as described previously.35 The mortality of the animals operated on in this manner was 30% within 48 h. Experimental animals were killed after 24, 48 h (e.g., acutely infarcted myocardium), as well as 2, 4 and 8 weeks (e.g., chronically infarcted) post-MI hearts, and cardiac tissues isolated from two left ventricular (HRP) regions, including remnant/viable (e.g., non-infarcted (NI)) LV free wall remote from the infarct scar and septum), and the infarct scar itself. Infarcted (e.g., pale, necrotic tissue in acutely infarcted versus overtly healed scar tissue in chronically infarcted animals) and non-infarcted (NI) regions were determined visually and compared with the same regions obtained from sham-operated rats. Samples were frozen in liquid N2 for subsequent western blotting analysis.

Statistical analysis. Results are expressed as means ± S.E.M., and statistical differences were determined by one- or two-way ANOVA, followed by Tukey’s or Bonferroni’s post hoc test using the Graph Pad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). A P-value of <0.05 was considered significant. Data were collected in triplicate from at least three separate cell cultures.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported with operating grants from the Canadian Institutes for Health Research and the Canadian Heart and Stroke Foundation (IMCD), and the laboratory is supported with funds provided by the St Boniface General Hospital and Research Foundation. A.J.H is a Canada Research Chair (Tier II) and S. Ghavami is supported by Parker B Francis Fellowship in Respiratory Disease and by the University of Manitoba start-up fund for young investigators. P.H. is supported by Eye’s High Postdoctoral Fellowship from the University of Calgary and Canadian National Transplant Research Program Academic Training Program. S. Gupta is supported with a studentship from the Institute of Cardiovascular Sciences at the University of Manitoba. E.A. is the recipient of a Research Manitoba Masters Award and B.Y. is supported by a Postdoctoral Fellowship from Research Manitoba.

1. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011; 51: 600–606.
2. Murarka S, Movahed MR. Diabetic cardiomypathy. J Card Fail 2010; 16: 971–979.
3. Gonzalez A, Lopez B, Quejreta R, Diez J. Regulation of myocardial fibribar collagen by angiotensin II: A role in hypertensive heart disease? J Mol Cell Cardiol 2002; 34: 1585–1593.
4. Brooks WW, Conrad CH. Myocardial fibrosis in transforming growth factor beta1 heterozygous mice. J Mol Cell Cardiol 2000; 32: 187–195.
5. Brand T, Schneider MD. Transforming growth factor-beta signal transduction. Circ Res 1996; 78: 173–179.
6. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133–146.
7. Hao J, Ju H, Zhao S, Junaid A, Scambell-Tifer T, Dixon M. Expression of Smad2, 3, and 4, and decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999; 31: 667–678.
8. Hao J, Wang B, Jones SC, Jassal DS, Dixon M. Interaction between angiotensin II and Smad proteins in fibrotic tissue in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000; 279:H320–H330.
9. Jali JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64: 1041–1050.
10. Brown L. Cardiac extracellular matrix: a dynamic entity. Am J Physiol Heart Circ Physiol 2000; 288:H973–H974.
11. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463–477.
12. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43: 67–93.
13. Ghavami S, Cunnigham RH, Yeganen B, Davies JJ, Rattan SG, Bathe K et al. Autophagy regulates trans fatty acid-mediated apoptosis in primary cardiac myofibroblasts. Biochim Biophys Acta 2012; 1823: 2274–2286.
14. Gong C, Baovy C, Toveil G, Yue W, Delomance C, Nicolas V et al. Beclin 1 and autophagy are required for the tumorigenesis of breast cancer stem-like/progenitor cells. Oncogene 2012; 31: 2281–2272.
15. Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME. Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-beta1. J Biol Chem 2012; 287: 11677–11688.
16. Mathew R, White E. Autophagy, stress, and cancer metabolism: what doesn’t kill you makes you stronger. Cold Spring Harbor Symp Quant Biol 2011; 76: 389–396.
17. Berry DL, Baehrecke EH. Autophagy functions in programmed cell death. Autophagy 2008; 4: 359–363.
18. Jangamreddy JR, Ghavami S, Grabarek J, Kratz G, Wiechec E, Fredriksson BA et al. Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cells. Biochim Biophys Acta 2013; 1833: 2057–2069.
Autophagy modulates heart fibrosis
S Ghavami et al

19. Yeganeh B, Rezaei Moghadam A, Tran AT, Rahim MN, Ande SR, Hashemi M et al. Asthma and influenza virus infection: focusing on cell death and stress pathways in influenza virus replication. Iran J Allergy Immunol Respir Dis 2013; 12: 1–17.

20. Ghavami S, Yeganeh B, Stelmack GL, Kashani HH, Sharma P, Cunningham R et al. Apoptosis, autophagy and ER stress in myelocandidase inhibition-induced cell death of human arial fibroblasts. Cell Death Dis 2012; 3: e630.

21. Ahn J, Kim J. Nutritional status and cardiac autophagy. Diabetes Meta J 2013; 37: 30–35.

22. Ren MY, Sui SJ. The role of TWEAK/Fn14 in cardiac remodeling. Chest 2011; 140: 649–657.

23. Harris J. Autophagy and cytokines. Cytochrome 2011; 56: 140–144.

24. Xu Y, Yang S, Huang J, Ruan S, Zhang Z, Li J. Tgf-beta1 induces autophagy and promotes apoptosis in renal tubular epithelial cells. J Int Med Res 2012; 40: 781–790.

25. Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J et al. Autophagy in idiopathic pulmonary fibrosis. PLoS One 2012; 7:e41154.

26. Liang A, Wang Y, Woodard LE, Wilson MH, Sharma R, Awasthi YC et al. Loss of glutathione S-transferase A4 accelerates obstruction-induced tubule damage and renal fibrosis. J Pathol 2012; 228: 448–458.

27. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z et al. Nutritional status and cardiac autophagy. Diabetes Met J 2012; 59: 9771–9777.

28. Sipido KR, Tedgui A, Kristensen SD, Pasterkamp G, Schunkert H, Wehling M et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad. J Clin Invest 2011; 120: 164–175.

29. Adam O, Lohfeld B, Thum T, Gupta SK, Puhl SL, Schafers HJ et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107: 278.

30. Ghavami S, Mutawe MM, Schafitza D, Yeganeh B, Unnun H, Klorisch T et al. Geranylgeranyl transferase 1 modulates autophagy and apoptosis in human coronary smooth muscle. Am J Physiol Lung Cell Mol Physiol 2012; 304: L420–L428.

31. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, Klorisch T et al. Myelocandidase regulation of arterial mesenchymal cell autophagy and apoptosis: a dual role for p53. PLoS One 2011; 6: e16603.

32. Klionsky DJ, Abdeliloh H, Agostini P, Akravig DK, Aliev G, Askew DS et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151–175.

33. Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin-converting enzyme inhibition and ventricular remodelling after myocardial infarction. Annu Rev Physiol 1995; 57: 805–826.

34. Lauer MS. Advancing cardiovascular research. J Clin Invest 2008; 121: 571–574.

35. Engelmann GL, Boehm KD, Birchenall-Roberts MC, Ruscetti FW. Transforming growth factor-beta1 transgenic in acute myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001; 282: H1499–H1686.

36. Mizushima N, Levine B, Cuervo AM. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069–1075.

37. Montpourn M, Esclatine A, Beau I, Codogno P. Autophagy in health and disease. 1. Regulation and significance of autophagy; an overview. Am J Physiol Cell Physiol 2002; 282: C776–C786.

38. Liou E, Markaki M, Tavaresmarins N. Autophagy and ageing: insights from invertebrate model organisms. Ageing Res Rev 2012; 12: 413–428.

39. Bolt AM, Klimczak WT. Autophagy in toxicology: self-consumption in times of stress and plenty. J Appl Toxicol 2013; 33: 462–475.

40. Kim G, Jun JB, Ekon KB. Necessary role of phosphatidylsilotin 3 kinase in transforming growth factor beta-mediated activation of Akt in normal and neumatoid arthritis synovial fibroblasts. Arthritis Rheum 2002; 46: 1504–1511.

41. Mazure NM, Pouysegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 2010; 22: 177–180.

42. Klionsky DJ, Abdalla FC, Abdeliloh H, Abraham RT, Acevedo-Arozena A, Adell K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.

43. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169–178.

44. Bolt AM, Klimecki WT. Autophagy in toxicology: self-consumption in times of stress and plenty. J Appl Toxicol 2013; 33: 462–475.

45. Fowler DF, Adams JC. Adhesion-modulating/matricellular ECM protein families: a functional, structural and evolutionary appraisal. Matrix Biol 2012; 31: 155–161.

46. Cunningham RH, Wang B, Ghavami S, Bathe KL, Rattan SG, Dixon IM. Antibiotic properties of C-Ski and its regulation of cardiac myofibroblast phenotype and contractility. Am J Physiol Cell Physiol 2011; 300: C178–C186.

47. Wyon TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199–210.

48. Rieder F, Fiocchi C. Intestinal fibrosis in IBD—a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6: 228–235.

49. Pelletin J, Lyon RC, Sheil E. Extracellular matrix remodelling in atrial fibrillation: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010; 48: 461–467.

50. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9: 129–140.

51. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2001; 2: 98–106.

52. Mosher DF, Adams JC. Adhesion-modulating/matricellular ECM protein families: a functional, structural and evolutionary appraisal. Matrix Biol 2012; 31: 155–161.

53. Lijen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta1. Mol Gen Metab 2000; 71: 418–435.

54. Talbot-Godein JM, Tsueng G, Rayen MP, Gottlieb RA, Feurer R. The role of autophagy during coxsackievirus infection of neural progenitor and stem cells. Autophagy 2012; 8: 938–953.

55. Chu PM, Chen LH, Chen MT, Ma Hi, Su TL, Hsieh PC et al. Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells. Cancer Chemother Pharmacol 2012; 69: 621–633.

56. Tsou LF, Guimaraes EL, Dolle L, Maonea S, Noked M, Sokal E et al. A role for autophagy during hepatic stellate cell activation. J Hepatol 2011; 55: 1353–1360.

57. Ucar A, Gupta SK, Fieder J, Erkici E, KardasiSins M, Batkai S et al. The miRNA-212:312 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2014; 5: 578.

58. Engellmann GL, Boehm KD, Birchard-Bo ROts MC, Ruscioti FW. Transforming growth factor-beta1 in heart development. Mech Dev 1992; 38: 85–97.

59. Engelman IM, Lee SL, Dhallia NS. Nitrinhibinin binding in congestive heart failure due to myocardial infarction. Cir Res 1990; 66: 782–788.

60. Merali WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. Am J Physiol Lung Cell Mol Physiol 2000; 278: L65–L78.